Skip to Main Content

4,618

Views

4

CrossRef citations to date

0

Altmetric

Articles

Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax

Evan C. Chena Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Yiwen Liub Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Courtney E. Harrisc Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USAView further author information

,

Eric S. Winera Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Martha Wadleigha Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Andrew A. Lanea Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Rahul S. Vedulaa Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

R. Coleman Lindsleya Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Kevin M. Copsona Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Anne Charlesa Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Francisco Martyc Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USAView further author information

,

Donna Neubergb Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Daniel J. DeAngeloa Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Richard M. Stonea Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Marlise R. Luskina Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

,

Nicolas C. Issac Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USAView further author information

&

Jacqueline S. Garciaa Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USACorrespondence[email protected]
View further author information